The Food and Drug Administration on Wednesday disputed a drug company’s claim that pharmacies can no longer produce less expensive versions of a drug long used to reduce the risk that women will give birth prematurely.
The statement was aimed at defusing a controversy that erupted after the agency approved the drug Makena to prevent preterm births. Makena’s owner, KV Pharmaceutical of St. Louis, is charging $1,500 a dose for the drug. The same compound had been available for years for about $10 to $20 a dose.
Health Glance
Home health agencies, hospitals and consumer groups are complaining that a new rule intended to curb unnecessary Medicare spending will make it harder for senior citizens to get home care services.
At the supermarket, most shoppers are oblivious to a battle raging within U.S. agriculture and the Obama administration’s role in it. Two thriving but opposing sectors — organics and genetically engineered crops — have been warring on the farm, in the courts and in Washington.





























